With so many companies focused on treating Crohn's disease lately you would think the likes of Takeda would be interested in licensing Remestemcel-L for UC and CD ?
If the reason we did not see an extension from Oaktree loan for the additional $30M is because they weren't interested, then that places even more 'pressure' on Mesoblast executives to license or sell off something .... only problem with that is any proposed licensee might see blood in the water IF that was the case and it 'leaked' and then they would really play hardball
Where is the CLBP deal ? Gregory surely didn't buy all those additional shares just to sit quiet in the background while nothing happens ?
Ann: Jane Bell Appointed Chair of Audit and Risk Committee, page-27
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |